Huiyu Pharmaceuticals has another new product to attack this year's fifth injection reported

Source: CDE Official Website Left beta-laxitan is a derivative of pyridoxine, suitable for the use of partial seizures (accompanied or not accompanied by secondary comprehensive seizures) in adults and children over 4 years of age.
the product was developed by a Belgian company and consists mainly of tablets, solutions and injections, which were approved by the FDA in July 2006 and approved for entry into the domestic market in July 2017. in recent years, sales at the end of public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) have increased year by year, with more than 1 billion yuan in 2019, up 12.54% year-on-year, according to
meters of intranet data.
left ethyl laxitan injection with thick solution in the domestic market late, has not yet formed a large-scale sales, in 2019 accounted for 2.1% of the overall market share of left ethyl lysidan, in 2020 H1 rose to 4.2%. figure
: Left ethyl laxitan injection with thick solution evaluation Source: Mi net consistency evaluation database There are currently 5 enterprises of the left elysethion injection with thick solution as through the consistent evaluation, respectively, Hebei Renyikang Pharmaceuticals, Jichuan Pharmaceuticals, Chongqing SanhuaYi Pharmaceuticals, Hainan Puli Pharmaceuticals and Jiangsu Wangao Pharmaceuticals, of which Hebei Renyikang Pharmaceuticals for the first evaluation. Table
: 2020 to date Sichuan Huiyu Pharmaceutical New Classification Product Species Source: Minet MED2.0 China Drug Review Database Minet data show that since 2020, Sichuan Huiyu Pharmaceuticals has five varieties of new classification, all injections.
prue shafu injection has not yet been approved for the market, currently by Sichuan Huiyu Pharmaceutical exclusive to the new classification of production.
source: MiNet database, CDE official website